Protein-protein interactions: Network analysis and applications in drug discovery

Current Pharmaceutical Design

Volumn 18, Issue 30, 2012, Pages 4619-4629

  Bultinck, Jennyfer ^a,b   Lievens, Sam ^a,b   Tavernier, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Drug discovery; Interactome; Oncology; Protein protein interaction; Small molecule; Virology

Indexed keywords

AEG 40826; AT 406; CG 049090; CHETOMIN; GDC 0152; IMIDAZOLINE DERIVATIVE; ISOSORBIDE; LCL 161; NAVITOCLAX; OBATOCLAX; PFK 115584; RRD 251; SJ 172550; STX 0119; UNCLASSIFIED DRUG;

ARTICLE; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; SACCHAROMYCES CEREVISIAE PROTEINS; SMALL MOLECULE LIBRARIES; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84866398910     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802651562     Document Type: Article

References (158)

1. Bunnage ME. Getting pharmaceutical R&D back on target. Nat Chem Biol 2011; 7(6): 335-339.
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5(12): 993-996.
3. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1(9): 727-730.
4. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996; 93(1): 13-20.
5. Moreira IS, Fernandes PA, Ramos MJ. Hot spots--a review of the protein-protein interface determinant amino-acid residues. Proteins 2007; 68(4): 803-812.
6. Clackson T, Wells JA. A hot spot of binding energy in a hormonereceptor interface. Science 1995; 267(5196): 383-386.
7. Arkin MR, Randal M, DeLano WL, et al. Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 2003; 100(4): 1603-1608.
8. Zhao HF, Kiyota T, Chowdhury S, et al. A mammalian genetic system to screen for small molecules capable of disrupting proteinprotein interactions. Anal Chem 2004; 76(10): 2922-2927.
9. Venkatesan K, Rual JF, Vazquez A, et al. An empirical framework for binary interactome mapping. Nat Methods 2009; 6(1): 83-90.
10. Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA 2008; 105(19): 6959-6964.
11. DrugBank. http://www.drugbank.ca/.
12. Gautier B, Miteva MA, Goncalves V, et al. Targeting the proangiogenic VEGF-VEGFR protein-protein interface with druglike compounds by in silico and in vitro screening. Chem Biol 2011; 18(12): 1631-1639.
13. Bertolini F, Marighetti P, Martin-Padura I, et al. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today 2011; 16(23/24): 1052-1060.
14. Garcia-Perez J, Rueda P, Alcami J, et al. Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). J Biol Chem 2011; 286(38): 33409-33421.
15. Domling A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr Opin Chem Biol 2008; 12(3): 281-291.
16. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303(5659): 844-848.
17. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8(1): 25-37.
18. Reed D, Shen Y, Shelat AA, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010; 285(14): 10786-10796.
19. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26(9): 1324-1337.
20. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16(3): 360-367.
21. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/home.
22. Albershardt TC, Salerni BL, Soderquist RS, et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem 2011; 286(28): 24882-24895.
23. Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Pat 2010; 20(2): 251-267.
24. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011; 15(7): 873-887.
25. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101(34): 12682-12687.
26. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 2011; 348: 139-149.
27. Davis RK, Chellappan S. Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer. Drug News Perspect 2008; 21(6): 331-335.
28. Kinkade R, Dasgupta P, Carie A, et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 2008; 68(10): 3810-3818.
29. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 2009; 284(39): 26831-26838.
30. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6(1): 33-43.
31. Ashizawa T, Miyata H, Ishii H, et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 2011; 38(5): 1245-1252.
32. Andersen RJ, Mawji NR, Wang J, et al. Regression of castraterecurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17(6): 535-546.
33. Moerke NJ, Aktas H, Chen H, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128(2): 257-267.
34. Cencic R, Hall DR, Robert F, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci USA 2011; 108(3): 1046-1051.
35. Zhao J, Du Y, Horton JR, et al. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci USA 2011; 108(39): 16212-16216.
36. White PW, Faucher AM, Goudreau N. Small molecule inhibitors of the human papillomavirus E1-E2 interaction. Curr Top Microbiol Immunol 2011; 348: 61-88.
37. White PW, Titolo S, Brault K, et al. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J Biol Chem 2003; 278(29): 26765-26772.
38. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007; 282(18): 13141-13145.
39. Smith JA, White EA, Sowa ME, et al. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc Natl Acad Sci USA 2010; 107(8): 3752-3757.
40. Yan J, Li Q, Lievens S, Tavernier J, You J. Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression. J Virol 2010; 84(1): 76-87.
41. Christ F, Voet A, Marchand A, et al. Rational design of smallmolecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010; 6(6): 442-448.
42. Tsantrizos YS, Boes M, Brock C, et al. Inhibitors of human immunodeficiency virus replication. PCT CA2007 2007.
43. Nathans R, Cao H, Sharova N, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 2008 Oct; 26(10): 1187-1192.
44. Cen S, Peng ZG, Li XY, et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem 2010; 285(22): 16546-16552.
45. Cencic R, Desforges M, Hall DR, et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol 2011; 85(13): 6381-6389.
46. Bordeleau ME, Robert F, Gerard B, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008; 118(7): 2651-2660.
47. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007; 117(9): 2638-2648.
48. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24(1): 71-109.
49. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 2011; 64(6): 413-425.
50. Andre E, Bastide L, Villain-Guillot P, Latouche J, Rouby J, Leonetti JP. A multiwell assay to isolate compounds inhibiting the assembly of the prokaryotic RNA polymerase. Assay Drug Dev Technol 2004; 2(6): 629-635.
51. Andre E, Bastide L, Michaux-Charachon S, et al. Novel synthetic molecules targeting the bacterial RNA polymerase assembly. J Antimicrob Chemother 2006; 57(2): 245-251.
52. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011; 79(1): 34-41.
53. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420(6913): 333-336.
54. Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 10(10): 1128-1132.
55. Chen T, Kablaoui N, Little J, et al. Identification of small-molecule inhibitors of the JIP-JNK interaction. Biochem J 2009; 420(2): 283-294.
56. Stebbins JL, De SK, Machleidt T, et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci USA 2008; 105(43): 16809-16813.
57. Zhang W, Penmatsa H, Ren A, et al. Functional regulation of cystic fibrosis transmembrane conductance regulator-containing macromolecular complexes: a small-molecule inhibitor approach. Biochem J 2011; 435(2): 451-462.
58. Florio SK, Loh C, Huang SM, et al. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br J Pharmacol 2009; 158(2): 494-506.
59. Meireles LM, Mustata G. Discovery of modulators of proteinprotein interactions: current approaches and limitations. Curr Top Med Chem 2011; 11(3): 248-257.
60. Colas P. High-throughput screening assays to discover smallmolecule inhibitors of protein interactions. Curr Drug Discov Technol 2008; 5(3): 190-199.
61. Lievens S, Caligiuri M, Kley N, Tavernier J. The use of mammalian two-hybrids for high-throughput drug screening. Methods. submitted.
62. Pagliaro L, Felding J, Audouze K, et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004; 8(4): 442-449.
63. Orry AJ, Abagyan RA, Cavasotto CN. Structure-based development of target-specific compound libraries. Drug Discov Today 2006; 11(5-6): 261-266.
64. Reynes C, Host H, Camproux AC, et al. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol 2010; 6(3): e1000695.
65. Sperandio O, Reynes CH, Camproux AC, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 2010; 15(5/6): 220-229.
66. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005; 437(7062): 1173-1178.
67. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005; 122(6): 957-968.
68. Ewing RM, Chu P, Elisma F, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 2007; 3: 89.
69. Bader GD, Betel D, Hogue CW. BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 2003; 31(1): 248-250.
70. Chatr-aryamontri A, Ceol A, Palazzi LM, et al. MINT: the Molecular INTeraction database. Nucleic Acids Res 2007; 35(Database issue): D572-D574.
71. Kerrien S, Alam-Faruque Y, Aranda B, et al. IntAct--open source resource for molecular interaction data. Nucleic Acids Res 2007; 35(Database issue): D561-D565.
72. Mishra GR, Suresh M, Kumaran K, et al. Human protein reference database--2006 update. Nucleic Acids Res 2006; 34(Database issue): D411-D414.
73. Pagel P, Kovac S, Oesterheld M, et al. The MIPS mammalian protein-protein interaction database. Bioinformatics 2005; 21(6): 832-834.
74. Reguly T, Breitkreutz A, Boucher L, et al. Comprehensive curation and analysis of global interaction networks in Saccharomyces cerevisiae. J Biol 2006; 5(4): 11.
75. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D. The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 2004; 32(Database issue): D449-D451.
76. Plewczynski D, Ginalski K. The interactome: predicting the protein-protein interactions in cells. Cell Mol Biol Lett 2009; 14(1): 1-22.
77. Skrabanek L, Saini HK, Bader GD, Enright AJ. Computational prediction of protein-protein interactions. Mol Biotechnol 2008; 38(1): 1-17.
78. Aragues R, Jaeggi D, Oliva B. PIANA: protein interactions and network analysis. Bioinformatics 2006; 22(8): 1015-1017.
79. Brown KR, Otasek D, Ali M, et al. NAViGaTOR: Network Analysis, Visualization and Graphing Toronto. Bioinformatics 2009; 25(24): 3327-3329.
80. Hu Z, Hung JH, Wang Y, et al. VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. Nucleic Acids Res 2009; 37(Web Server issue): W115-W121.
81. Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 2011; 696: 291-303.
82. Breitkreutz BJ, Stark C, Tyers M. Osprey: a network visualization system. Genome Biol 2003; 4(3): R22.
83. Chang AN, McDermott J, Frazier Z, Guerquin M, Samudrala R. INTEGRATOR: interactive graphical search of large protein interactomes over the Web. BMC Bioinformatics 2006; 7: 146.
84. Kushwaha SK, Shakya M. PINAT1.0: protein interaction network analysis tool. Bioinformation 2009; 3(10): 419-421.
85. Aranda B, Achuthan P, Alam-Faruque Y, et al. The IntAct molecular interaction database in 2010. Nucleic Acids Res 2010; 38(Database issue): D525-D531.
86. Stark C, Breitkreutz BJ, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS, et al. The BioGRID Interaction Database: 2011 update. Nucleic Acids Res 2011; 39(Database issue): D698-D704.
87. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006; 34(Database issue): D535-D539.
88. Prasad TS, Kandasamy K, Pandey A. Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol 2009; 577: 67-79.
89. Lehne B, Schlitt T. Protein-protein interaction databases: keeping up with growing interactomes. Hum Genomics 2009; 3(3): 291-297.
90. Batada NN, Hurst LD, Tyers M. Evolutionary and physiological importance of hub proteins. PLoS Comput Biol 2006; 2(7): e88.
91. Gandhi TK, Zhong J, Mathivanan S, et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 2006; 38(3): 285-293.
92. von Mering C, Krause R, Snel B, et al. Comparative assessment of large-scale data sets of protein-protein interactions. Nature 2002; 417(6887): 399-403.
93. Braun P, Tasan M, Dreze M, et al. An experimentally derived confidence score for binary protein-protein interactions. Nat Methods 2009; 6(1): 91-97.
94. Cusick ME, Yu H, Smolyar A, et al. Literature-curated protein interaction datasets. Nat Methods 2009; 6(1): 39-46.
95. Simonis N, Rual JF, Carvunis AR, et al. Empirically controlled mapping of the Caenorhabditis elegans protein-protein interactome network. Nat Methods 2009; 6(1): 47-54.
96. Turinsky AL, Razick S, Turner B, Donaldson IM, Wodak SJ. Literature curation of protein interactions: measuring agreement across major public databases. Database (Oxford) 2010; 2010: baq026.
97. Orchard S, Salwinski L, Kerrien S, et al. The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol 2007; 25(8): 894-898.
98. Yu H, Braun P, Yildirim MA, et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008; 322(5898): 104-110.
99. Puts CF, Lenoir G, Krijgsveld J, Williamson P, Holthuis JC. A P4-ATPase protein interaction network reveals a link between aminophospholipid transport and phosphoinositide metabolism. J Proteome Res 2010; 9(2): 833-842.
100. Zhang H, Tang X, Munske GR, Tolic N, Anderson GA, Bruce JE. Identification of protein-protein interactions and topologies in living cells with chemical cross-linking and mass spectrometry. Mol Cell Proteomics 2009; 8(3): 409-420.
101. Leitner A, Walzthoeni T, Kahraman A, et al. Probing native protein structures by chemical cross-linking, mass spectrometry, and bioinformatics. Mol Cell Proteomics 2010; 9(8): 1634-1649.
102. Rinner O, Seebacher J, Walzthoeni T, et al. Identification of crosslinked peptides from large sequence databases. Nat Methods 2008; 5(4): 315-318.
103. Sardiu ME, Cai Y, Jin J, et al. Probabilistic assembly of human protein interaction networks from label-free quantitative proteomics. Proc Natl Acad Sci USA 2008; 105(5): 1454-1459.
104. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138(2): 389-403.
105. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010; 466(7302): 68-76.
106. Hutchins JR, Toyoda Y, Hegemann B, et al. Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science 2010 Apr 30; 328(5978): 593-599.
107. Lievens S, Lemmens I, Tavernier J. Mammalian two-hybrids come of age. Trends Biochem Sci 2009; 34(11): 579-588.
108. Petschnigg J, Snider J, Stagljar I. Interactive proteomics research technologies: recent applications and advances. Curr Opin Biotechnol 2011; 22(1): 50-58.
109. Lemmens I, Lievens S, Tavernier J. Strategies towards high-quality binary protein interactome maps. J Proteomics 2010; 73(8): 1415-1420.
110. Yu H, Tardivo L, Tam S, et al. Next-generation sequencing to generate interactome datasets. Nat Methods 2011; 8(6): 478-480.
111. Oti M, Snel B, Huynen MA, Brunner HG. Predicting disease genes using protein-protein interactions. J Med Genet 2006; 43(8): 691-698.
112. Fraser HB, Plotkin JB. Using protein complexes to predict phenotypic effects of gene mutation. Genome Biol 2007; 8(11): R252.
113. Kohler S, Bauer S, Horn D, Robinson PN. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 2008; 82(4): 949-958.
114. Lage K, Karlberg EO, Storling ZM, et al. A human phenomeinteractome network of protein complexes implicated in genetic disorders. Nat Biotechnol 2007; 25(3): 309-316.
115. Wu X, Jiang R, Zhang MQ, Li S. Network-based global inference of human disease genes. Mol Syst Biol 2008; 4: 189.
116. Karni S, Soreq H, Sharan R. A network-based method for predicting disease-causing genes. J Comput Biol 2009; 16(2): 181-189.
117. Hwang S, Son SW, Kim SC, Kim YJ, Jeong H, Lee D. A protein interaction network associated with asthma. J Theor Biol 2008; 252(4): 722-731.
118. Liu M, Liberzon A, Kong SW, et al. Network-based analysis of affected biological processes in type 2 diabetes models. PLoS Genet 2007; 3(6): e96.
119. Jesmin J, Rashid MS, Jamil H, Hontecillas R, Bassaganya-Riera J. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genomics 2010; 3(1): 45.
120. Wang K, Zhang H, Kugathasan S, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 2009; 84(3): 399-405.
121. Jensen MK, Pers TH, Dworzynski P, Girman CJ, Brunak S, Rimm EB. Protein Interaction-Based Genome-Wide Analysis of Incident Coronary Heart Disease. Circ Cardiovasc Genet 2011; 4(5): 549-556.
122. Pujana MA, Han JD, Starita LM, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007; 39(11): 1338-1349.
123. Lee E, Jung H, Radivojac P, Kim JW, Lee D. Analysis of AML genes in dysregulated molecular networks. BMC Bioinformatics 2009; 10 Suppl 9: S2.
124. Mani KM, Lefebvre C, Wang K, et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in Bcell lymphomas. Mol Syst Biol 2008; 4: 169.
125. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007; 3: 140.
126. Su J, Yoon BJ, Dougherty ER. Identification of diagnostic subnetwork markers for cancer in human protein-protein interaction network. BMC Bioinformatics 2010; 11 Suppl 6: S8.
127. Chowdhury SA, Koyuturk M. Identification of coordinately dysregulated subnetworks in complex phenotypes. Pac Symp Biocomput 2010: 133-144.
128. Nibbe RK, Markowitz S, Myeroff L, Ewing R, Chance MR. Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics 2009; 8(4): 827-845.
129. Chang W, Ma L, Lin L, et al. Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer 2009 Dec 15; 125(12): 2844-2853.
130. Taylor IW, Linding R, Warde-Farley D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009 Feb; 27(2): 199-204.
131. Dao P, Wang K, Collins C, Ester M, Lapuk A, Sahinalp SC. Optimally discriminative subnetwork markers predict response to chemotherapy. Bioinformatics 2011; 27(13): i205-i213.
132. Jorgensen KM, Hjelle SM, Oye OK, et al. Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia. J Proteomics 2011; 74(3): 269-281.
133. Chavez JD, Hoopmann MR, Weisbrod CR, Takara K, Bruce JE. Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells. PLoS One 2011; 6(5): e19892.
134. Guo Y, Zhu XD, Qu S, et al. Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. Int J Oncol 2011 Aug 19.
135. Kim J, Woo AJ, Chu J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143(2): 313-324.
136. Lim J, Hao T, Shaw C, et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006; 125(4): 801-814.
137. Goehler H, Lalowski M, Stelzl U, et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004; 15(6): 853-865.
138. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007; 3(5): e82.
139. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20(3): 146-154.
140. Camargo LM, Collura V, Rain JC, et al. Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 2007; 12(1): 74-86.
141. Romero E, Cha GH, Verstreken P, et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008; 57(1): 27-40.
142. Calderwood MA, Venkatesan K, Xing L, et al. Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci USA 2007; 104(18): 7606-7611.
143. de Chassey B, Navratil V, Tafforeau L, et al. Hepatitis C virus infection protein network. Mol Syst Biol 2008; 4: 230.
144. Bailer SM, Haas J. Connecting viral with cellular interactomes. Curr Opin Microbiol 2009; 12(4): 453-459.
145. Uetz P, Dong YA, Zeretzke C, et al. Herpesviral protein networks and their interaction with the human proteome. Science 2006; 311(5758): 239-242.
146. Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, Neff C, et al. Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J Proteome Res 2009; 8(9): 4311-4318.
147. Shapira SD, Gat-Viks I, Shum BO, et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 2009; 139(7): 1255-1267.
148. Khadka S, Vangeloff AD, Zhang C, et al. A physical interaction network of dengue virus and human proteins. Mol Cell Proteomics 2011 Sep 12.
149. Simonis N RJ, Lemmens I, Hirozane-Kishikawa T, et al. Hostpathogen interactome mapping for HTLV-1 and -2 retroviruses. Retrovirology. submitted.
150. Jager S, Gulbahce N, Cimermancic P, et al. Purification and characterization of HIV-human protein complexes. Methods 2011; 53(1): 13-19.
151. Komarova AV, Combredet C, Meyniel-Schicklin L, et al. Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses. Mol Cell Proteomics 2011 Sep 12.
152. Dyer MD, Murali TM, Sobral BW. The landscape of human proteins interacting with viruses and other pathogens. PLoS Pathog 2008; 4(2): e32.
153. Navratil V, de Chassey B, Combe CR, Lotteau V. When the human viral infectome and diseasome networks collide: towards a systems biology platform for the aetiology of human diseases. BMC Syst Biol 2011; 5: 13.
154. Brodsky IE, Medzhitov R. Targeting of immune signaling networks by bacterial pathogens. Nat Cell Biol 2009; 11(5): 521-526.
155. Dyer MD, Neff C, Dufford M, et al. The human-bacterial pathogen protein interaction networks of Bacillus anthracis, Francisella tularensis, and Yersinia pestis. PLoS One 2010; 5(8): e12089.
156. Yang H, Ke Y, Wang J, et al. Insight into bacterial virulence mechanisms against host immune response via Y. pestis-human protein-protein interaction network. Infect Immun 2011 Sep 12.
157. Fugier E, Salcedo SP, de Chastellier C, et al. The glyceraldehyde- 3-phosphate dehydrogenase and the small GTPase Rab 2 are crucial for Brucella replication. PLoS Pathog 2009; 5(6): e1000487.
158. de Barsy M, Jamet A, Filopon D, et al. Identification of a Brucella spp. secreted effector specifically interacting with human small GTPase Rab2. Cell Microbiol 2011; 13(7): 1044-1058.